Search Result

Results for "

proliferator-activated

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (50) Adiponectin Receptor (1) Akt (2) AMPK (1) Amyloid-β (2) Apoptosis (4) Aryl Hydrocarbon Receptor (1) Autophagy (2) Bacterial (2) Cytochrome P450 (1) Endogenous Metabolite (4) Epoxide Hydrolase (1) Estrogen Receptor/ERR (1) Ferroptosis (3) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (2) Isotope-Labeled Compounds (1) Leukotriene Receptor (1) LXR (3) PARP (1) PGC-1α (3) Ras (1) Reactive Oxygen Species (3) Sirtuin (1) Tau Protein (1) TGF-β Receptor (1) VD/VDR (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (9) Metabolic Disease (46) Neurological Disease (5)

By Targets:

PPAR (50)

Adiponectin Receptor (1)

Akt (2)

AMPK (1)

Amyloid-β (2)

Apoptosis (4)

Aryl Hydrocarbon Receptor (1)

Autophagy (2)

Bacterial (2)

Cytochrome P450 (1)

Endogenous Metabolite (4)

Epoxide Hydrolase (1)

Estrogen Receptor/ERR (1)

Ferroptosis (3)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (2)

Isotope-Labeled Compounds (1)

Leukotriene Receptor (1)

LXR (3)

PARP (1)

PGC-1α (3)

Ras (1)

Reactive Oxygen Species (3)

Sirtuin (1)

Tau Protein (1)

TGF-β Receptor (1)

VD/VDR (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (5)

Infection (1)

Inflammation/Immunology (9)

Metabolic Disease (46)

Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: PPAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134377

Bocidelpar ASP0367; MA-0211	PPAR	Metabolic Disease
Bocidelpar is a modulator of *peroxisome proliferator-activated* receptor delta (PPAR-δ**). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b) .

HY-121538

CUDA	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases *peroxisome proliferator-activated* receptor (PPAR) alpha** activity. CUDA may be valuable for the research of cardiovascular disease .

HY-15577

GSK3787 10+ Cited Publications	PPAR	Cancer
GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC₅₀ of 6.6.

HY-130479

AdipoR agonist 1	Adiponectin Receptor PPAR PGC-1α Sirtuin AMPK	Metabolic Disease
AdipoR agonist 1 (Compound 112254) is an agonist for adiponectin receptor (AdipoR), which activates the transcriptional regulators like peroxisome proliferator-activated receptors (PPARs), peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), and adenylate-activated protein kinase (AMPK). AdipoR agonist 1 is utilized in preventive doping research .

HY-17538

ZLN005 Maximum Cited Publications 32 Publications Verification	PGC-1α Autophagy	Metabolic Disease
ZLN005 is a potent activator of *peroxisome proliferator-activated* receptor-γ coactivator-1α (PGC-1α)** .

HY-153344

FX-909	PPAR	Cancer
FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer .

HY-113820

AZD4619	PPAR	Metabolic Disease
AZD4619 is an orally active, selective *peroxisome proliferator-activated* receptor α (PPARα)** agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .

HY-14831

Arhalofenate MBX 102; JNJ 39659100	PPAR	Metabolic Disease
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.

HY-101746

GSK376501A	PPAR	Metabolic Disease
GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus .

HY-120188

CC618	PPAR	Others
CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors .

HY-101637

Reglitazar JT 501	PPAR	Metabolic Disease
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .

HY-U00036A

Naveglitazar LY519818	PPAR	Metabolic Disease
Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .

HY-19937

Saroglitazar 5 Publications Verification	PPAR	Metabolic Disease
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-19937A

Saroglitazar magnesium 5 Publications Verification	PPAR	Metabolic Disease
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-N3026

Soyasaponin Ab 1 Publications Verification	PPAR	Metabolic Disease
Soyasaponin Ab is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ) .

HY-N3027

Soyasaponin Aa	PPAR	Metabolic Disease
Soyasaponin Aa is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ) .

HY-U00036

Naveglitazar racemate LY519818 racemate	PPAR	Metabolic Disease
Naveglitazar racemate (LY519818 racemate) is the racemate of Naveglitazar. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .

HY-120160A

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-128344

BR102375	PARP Apoptosis	Metabolic Disease
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC₅₀ value of 0.28 μM and A_max ratio of 98% .

HY-113473

10-Nitrolinoleic acid	PPAR	Metabolic Disease Inflammation/Immunology Cancer
10-Nitrolinoleic acid is a potent peroxisome proliferator-activated receptor γ (PPARγ) agonist. 10-Nitrolinoleic acid competes with [ ³H]Rosiglitazone for binding to PPAR-γ, with an IC₅₀ of 0.22 μM .

HY-122083

T2384	PPAR	Metabolic Disease
T2384 is a *peroxisome proliferator-activated* receptor γ (PPARγ)** ligand. T2384 also is an orally active antidiabetic agent. T2384 reduces the fasting plasma glucose levels and plasma insulin levels .

HY-108572

S26948	PPAR	Cardiovascular Disease Metabolic Disease
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC₅₀=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ .

HY-118514

CAY10514	PPAR	Metabolic Disease
CAY10514 is an aromatic of 8(S)-HETE. CAY10514 acts as a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ with IC₅₀ of 0.173 and 0.642 μM, respectively .

HY-17538S

ZLN005-d4	PGC-1α Autophagy	Metabolic Disease
ZLN005-d₄ is deuterium labeled ZLN005. ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α)[1].

HY-13956C

(R)-Pioglitazone (R)-U 72107	PPAR	Neurological Disease
(R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .

HY-N1990

Gypenoside XLIX	PPAR	Cardiovascular Disease Inflammation/Immunology
Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective *peroxisome proliferator-activated* receptor (PPAR)-alpha** activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-19937S1

Saroglitazar-d4	Isotope-Labeled Compounds	Others
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-15655

GW1929 5+ Cited Publications	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active *peroxisome proliferator-activated* receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ**, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

HY-13956

Pioglitazone 25+ Cited Publications U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-13956B

Pioglitazone potassium U 72107 potassium	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .

HY-163443

PPAR agonist 4	PPAR	Others
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC₅₀s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .

HY-115357

BMS711939	PPAR	Metabolic Disease
BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC₅₀ of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .

HY-N0246

Saikosaponin A 1 Publications Verification	LXR Bacterial	Inflammation/Immunology Cancer
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-155704

Lyciumamide A	Others	Others
DPP-IV-IN-5 is isolated from the fruits of Lycium barbarum. DPP-IV-IN-5 exerts moderate agonistic activities for peroxisome proliferator-activated receptor (PPARγ) with EC₅₀ values of 10.09 - 44.26 μM and also presents inhibitory activity on dipeptidyl peptidase-4 (DPPIV) with an IC₅₀ value of 47.13 μM .

HY-117103

AMG131 INT131	PPAR	Metabolic Disease
AMG131 (INT131) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 binds to PPARγ within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 is promising for research of type-2 diabetes mellitus .

HY-106181A

Rivoglitazone hydrochloride R-106056 hydrochloride	PPAR	Metabolic Disease
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .

HY-117103A

AMG131 benzenesulfonate INT131 benzenesulfonate	PPAR	Metabolic Disease
AMG131 (INT131) (benzenesulfonate) is a potent non-thiazolidinedione (TZD) selective *peroxisome proliferator-activated* receptor γ modulator (SPPARM). AMG131 (benzenesulfonate) binds to PPARγ** within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 (benzenesulfonate) is promising for research of type-2 diabetes mellitus .

HY-13956R

Pioglitazone (Standard)	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-110022

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active *peroxisome proliferator-activated* receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis** and shows anti-inflammatory potential .

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-17444

Tesaglitazar	PPAR	Metabolic Disease Cancer
Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with EC₅₀s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively, and approximately 0.2 μM for both rat and human PPARγ. Tesaglitazar induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats .

HY-N0246R

Saikosaponin A (Standard)	LXR Bacterial	Metabolic Disease Inflammation/Immunology
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-117459

E-3030 free acid	Others	Metabolic Disease
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.

HY-101676

RG-12525 NID 525	Leukotriene Receptor PPAR Cytochrome P450	Metabolic Disease
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC₅₀ of appr 60 nM and a potent inhibitor of CYP3A4, with a K_i value of 0.5 µM.

HY-121888

20-HEPE	Others	Metabolic Disease
20-HEPE is a metabolite of eicosapentaenoic acid formed by ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. At 10 μM, it activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter gene. 20-HEPE also activates mouse transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks analgesic activity in rats.

HY-77278

25-Hydroxytachysterol3	VD/VDR Aryl Hydrocarbon Receptor LXR PPAR	Others
25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-168049

ZLY06	PPAR Akt	Metabolic Disease
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .

HY-N11507

Tibesaikosaponin V TKV	PPAR	Metabolic Disease
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as *peroxisome proliferator-activated* receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα**). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .

Cat. No.	Compare	Product Name	Species	Source

HY-P701336

	PPAR gamma Protein, Human PPARG; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with tag free. The total length of PPAR gamma Protein, Human is 272 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17538S

ZLN005-d4
ZLN005-d₄ is deuterium labeled ZLN005. ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α)[1].

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80871

	PPAR alpha Antibody PPARA; NR1C1; PPAR; Peroxisome proliferator-activated receptor alpha; PPAR-alpha; Nuclear receptor subfamily 1 group C member 1	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	PPAR alpha Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 52 kDa, targeting to PPAR alpha. It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat.

HY-P80783

	PGC1 alpha Antibody PPARGC1A; LEM6; PGC1; PGC1A; PPARGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; PPAR-gamma coactivator 1-alpha; PPARGC-1-alpha; Ligand effect modulator 6	WB	Human, Mouse, Rat
	PGC1 alpha Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 91 kDa, targeting to PGC1 alpha. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P80872

	PPAR gamma Antibody CIMT1; GLM1; NR1C3; Nuclear receptor subfamily 1 group C member 3; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome proliferator activated Receptor gamma; Peroxisome prolife	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	PPAR gamma Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 58 kDa, targeting to PPAR gamma. It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks